The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
Search results for: psoriasis
Finding the Panacea: The Management of Psoriatic Arthritis
In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
FDA Approves Ustekinumab-stba for All Forms & Dosages as Its Reference Product
Ustekinumab-stba (Steqeyma) now has FDA approval for all forms and dosages of its reference product, ustekinumab (Stelara), including a subcutaneous injection to treat pediatric patients with plaque psoriasis or psoriatic arthritis.
Highlights from the European Congress of Internal Medicine
An overview of highlights from the 2025 ECIM meeting, including research on treatment options for systemic sclerosis, the management of PMR & autoimmune testing.
Incarcerated Individuals with Rheumatic Conditions
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
ACR Leaders Discuss Rheumatology Medications at Medicare Drug Price Negotiation Town Hall
On April 30, Rebecca Shepherd, MD, MBA, and Amanda Myers, MD, represented rheumatology in a live town hall on the Medicare Drug Price Negotiation Program, describing the benefits of apremilast and nintedanib for patients with rheumatic disease.
In the Details: Diagnosing PsA Requires Drilling Down
Rheumatologists must do some detective work into a patient’s signs and symptoms when considering a psoriatic arthritis diagnosis, according to Philip J. Mease, MD, MACR
Deucravacitinib Promising for PsA
Results from two studies found that deucravacitinib improved the signs and symptoms of patients with psoriatic arthritis who were biologic disease-modifying anti-rheumatic drug naive and those previously treated with a tumor necrosis factor α inhibitor.
FDA Approval Sought for 2 Pediatric Indications for Guselkumab
The FDA is reviewing supplemental biologics license applications for guselkumab to treat children with juvenile psoriatic arthritis and moderate to severe plaque psoriasis.
ACR Image Competition 2024 Results, Part 3
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from Latin America and the Caribbean. Diagnosing Juvenile PsA A 13-year-old boy presented with a seven-year history of…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 56
- Next Page »